<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651362</url>
  </required_header>
  <id_info>
    <org_study_id>2015_26</org_study_id>
    <secondary_id>2015-A01159-40</secondary_id>
    <nct_id>NCT03651362</nct_id>
  </id_info>
  <brief_title>Linking Optic Nerve MRI and the Retinal Axonal Loss After Optic Neuritis</brief_title>
  <acronym>IRMANO</acronym>
  <official_title>Linking Optic Nerve Lesion Length at MRI and the Retinal Axonal Loss at 12 Months From a Clinical Episode of Optic Neuritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the length of optic nerve lesion on 3D-DIR sequence as an imaging
      biomarker predictive of retinal axonal loss and visual disability, 12 months after the
      occurence of a first clinical episode of optic neuritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurologists and Neuro-Ophthalmologists are in need for reliable and robust imaging
      biomarkers enabling to predict retinal axonal loss and visual disability after clinical
      episode of optic neuritis (ON). Length of optic nerve lesion measured on MRI may be one of
      them.

      The aim of our study is to measure the association between the extent of inflammatory
      demyelinating process on optic nerve at the acute of ON and the retinal degenerative process
      following optic nerve injury.

      The investigators planned to include 50 patients suffering from a recent clinical episode of
      ON.

      Extent of demyelinating inflammatory process will be assessed by the length of optic nerve
      double inversion recovery (DIR) hypersignal at the acute phase of ON.

      The axonal degenerative process following optic nerve demyelinating injury will be assessed
      by retinal atrophy measured on optical coherence tomography at 12 months after ON, by visual
      disability measured on low vision contrast acuity scale and by microstructural quality
      analysis of optic nerve measured on diffusion tensor imaging sequence of the optic nerve.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of retinal axonal loss around papilla after a clinical episode of optic neuritis</measure>
    <time_frame>12 months</time_frame>
    <description>peripapillary RNFL thickness decrease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of retinal axonal loss within macula after a clinical episode of optic neuritis</measure>
    <time_frame>12 months</time_frame>
    <description>macular volume decrease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of visual disability after a clinical episode of optic neuritis</measure>
    <time_frame>12 months</time_frame>
    <description>monocular low contrast (2.5%) vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of microstructural architecture of optic nerve after a clinical episode of optic neuritis</measure>
    <time_frame>12 months</time_frame>
    <description>fractional anisotropy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of optic nerve lesion length</measure>
    <time_frame>12 months</time_frame>
    <description>lesion length in mm measured on 3D-double inversion recovery sequence</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Optic Neuritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from a recent clinical episode of ON suggestive of demyelinating disease
        as clinically isolated syndrome, multiple sclerosis or neuromyelitis optica spectrum
        disorders.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient suffering from an acute clinical episode of optic neuritis (ON) confirmed by
             neurophthalmological examination

          -  &lt; 2 months between start of acute episode of ON and inclusion

        Exclusion Criteria:

          -  past history of homolateral episode of ON

          -  retinal diseases

          -  diabeta mellitus

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Outteryck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Outteryck, MD, PhD</last_name>
    <email>olivier.outteryck@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Outteryck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hadhoum N, Hodel J, Defoort-Dhellemmes S, Duhamel A, Drumez E, Zéphir H, Pruvo JP, Leclerc X, Vermersch P, Outteryck O. Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss. Mult Scler. 2016 Apr;22(5):649-58. doi: 10.1177/1352458515598021. Epub 2015 Jul 30.</citation>
    <PMID>26227005</PMID>
  </reference>
  <reference>
    <citation>Hodel J, Outteryck O, Bocher AL, Zéphir H, Lambert O, Benadjaoud MA, Chechin D, Pruvo JP, Vermersch P, Leclerc X. Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study. Eur Radiol. 2014 Dec;24(12):3069-75. doi: 10.1007/s00330-014-3342-3. Epub 2014 Aug 23.</citation>
    <PMID>25149294</PMID>
  </reference>
  <reference>
    <citation>Miller DH, Newton MR, van der Poel JC, du Boulay EP, Halliday AM, Kendall BE, Johnson G, MacManus DG, Moseley IF, McDonald WI. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. 1988 Feb;38(2):175-9.</citation>
    <PMID>3340276</PMID>
  </reference>
  <reference>
    <citation>Dunker S, Wiegand W. Prognostic value of magnetic resonance imaging in monosymptomatic optic neuritis. Ophthalmology. 1996 Nov;103(11):1768-73.</citation>
    <PMID>8942868</PMID>
  </reference>
  <reference>
    <citation>Kallenbach K, Simonsen H, Sander B, Wanscher B, Larsson H, Larsen M, Frederiksen JL. Retinal nerve fiber layer thickness is associated with lesion length in acute optic neuritis. Neurology. 2010 Jan 19;74(3):252-8. doi: 10.1212/WNL.0b013e3181ca0135.</citation>
    <PMID>20083802</PMID>
  </reference>
  <reference>
    <citation>Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005 Sep;58(3):383-91.</citation>
    <PMID>16075460</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>optic neuritis</keyword>
  <keyword>DIR</keyword>
  <keyword>visual disability</keyword>
  <keyword>CIS</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>NMOSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

